跳至主要内容
临床试验/CTRI/2026/07/113277
CTRI/2026/07/113277招募中不适用

A Multicentric, Prospective Study To Generate Real World Evidence On The Use Of Vitamin K Antagonists In Valvular Heart Disease In India - NIL

Abbott Healthcare Private Limited0 个研究点目标入组 500 人开始时间: 2026年7月10日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Subjects must meet all of the following inclusion criteria to be eligible for participation in this study
  • 1 Adult patients of either sex, aged greater than equal to 18 to less than equal to 80 years
  • 2 Patients with a recent diagnosis of valvular heart disease VHD who have been initiated on treatment with oral Vitamin K Antagonists VKAs acenocoumarol or warfarin, as per the treating physicians clinical judgment, for one of the following indications.
  • a. VHD Patients Undergoing Valve Replacement Surgery.
  • b. Patient undergoing valve repair procedures started on VKAs post intervention.
  • 3 Patients willing and able to provide written informed consent.

排除标准

  • Subjects who meet any of the following exclusion criteria are not to be enrolled in this study
  • Patients with renal impairment & not suited for VKA treatment as per investigators judgement
  • Patients with significant liver disease i.e. cirrhosis and not suited for VKA treatment as per investigators judgement
  • Patients with active or high-risk bleeding
  • Patients not willing to sign PAF
  • Patients with alcohol abuse
  • Patients who are allergic or intolerant to Acenocoumarol and Warfarin.
  • Pregnancy or breastfeeding women

研究者

相似试验

A Clinical Study to Generate Real World Evidence on... | 临床试验